Report Category

Pharmaceutical Market Research Reports

In-depth market intelligence covering drug development, CDMO outsourcing, API manufacturing, biosimilars, oncology, cell & gene therapy, clinical trials, and specialty pharma — with 10-year forecasts, 15–25 KOL interviews per report, and competitive landscape analysis.

340+
Reports
10yr
Forecasts
15–25
KOL Interviews

Pharmaceutical Industry Market Intelligence

The global pharmaceutical market continues to evolve rapidly, driven by the acceleration of biologics and biosimilar development, the expansion of CDMO outsourcing models, advances in cell and gene therapy manufacturing, and the growing demand for complex drug delivery systems. InsightAce Analytic's pharmaceutical report library covers the full value chain — from active pharmaceutical ingredient sourcing and continuous manufacturing to clinical trial logistics and post-market commercialization.

CDMO & Contract ManufacturingOutsourcing models, capacity analysis, competitive positioning
API & Drug SubstanceSupply chain, HPAPI, peptide APIs, oligonucleotides
Oncology & Immuno-OncologyADCs, bispecifics, CAR-T, radiopharmaceuticals
Drug Delivery SystemsLNP platforms, nasal, transdermal, implantable devices
Biosimilars & BiologicsPatent cliffs, pipeline analysis, market penetration
Cell & Gene TherapyManufacturing, logistics, vein-to-vein supply chain
Clinical Trials & CRODecentralized trials, site management, real-world evidence
Rare Diseases & Orphan DrugsRegulatory pathways, pricing, competitive dynamics
CNS & NeurologyNeurodegeneration, psychiatric, digital therapeutics

Catastrophic Antiphospholipid Syndrome Market Size, Share & Trends Analysis Report, By Treatment (Anticoagulants, Immunosuppressive Therapy, Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG) and Others), By End-use (Hospitals, Clinics, Others), By Region, Forecasts, 2024-2031

The Catastrophic Antiphospholipid Syndrome Market Size was valued at USD 4.38 Bn in 2023 and is predicted to reach USD 9.34 Bn by 2031 at a 10.2% CAGR during the forecast period for 2024-2031. Catastrophic antiphospholipid syndrome refers to an uncommon immunological condition marked by persistent antiphospholipid antigens, chronic arterial or venous embolism, and reproductive mortality. It is more common in women and may develop as eithe...

ID: 2786 180 Pages September 2024

Longevity and Anti-Senescence Therapy Market Size, Share & Trends Analysis Report By Therapy (Senolytic Drug Therapy, Gene Therapy, Cell Therapy, Mitochondrial Therapy, Immunotherapy, Others), By Application, By Region, And By Segment Forecasts, 2024-2031

The Longevity and Anti-Senescence Therapy Market Size is valued at USD 2,736.43 million in 2023 and is predicted to reach USD 4,121.54 million by the year 2030 at a 6.8 % CAGR during the forecast period for 2024-2030. Longevity is an effective approach focuses on the extension of health span by slowing the rate of aging. This approach is considered as the most efficient way to combat various aging-related chronic illnesses and disabling condit...

ID: 1354 180 Pages September 2024

Oligonucleotide Delivery System Market Size, Share & Trends Analysis Distribution by Delivery System (Conjugation-Based Delivery Systems (GALNAc Conjugation, Ligand Conjugation, Antibody Conjugation, Targeting Moiety Conjugation), Nanoparticle-Based Delivery Systems (Lipid Nanoparticles (LNPs), Peptide Nanoparticles), Viral Vector-Based Delivery Systems (Adeno-associated Virus (AAV) Vectors, AAV9, Lentiviral Vectors, Others), Exosome-Based Delivery Systems, Liposomes, Others), Disease Indication and Segment Forecasts, 2024-2031

The Oligonucleotide Delivery System Market is predicted to grow at an 12.4% CAGR during the forecast period for 2024-2031. The delivery system of an oligonucleotide refers to the method and technologies applied for transferring oligonucleotides into cells where they could exert their therapeutic effects. Oligonucleotides, due to their size and chemical properties, face the challenge of penetration through the biological barriers to enter targe...

ID: 2779 180 Pages September 2024

Lipid-Based Drug Delivery Systems Market Size, Share & Trends Analysis Distribution by Type of Lipid-Based System (Liposomes, Solid Lipid Nanoparticles (SLNs), Nanostructured Lipid Carriers (NLCs), Lipid Nanoparticles (LNPs), Micelles, Lipid-Polymer Hybrid Systems), Application, Route of Administration, Formulation and Segment Forecasts, 2024-2031

The Lipid-Based Drug Delivery Systems Market Size is predicted to grow with a an CAGR of 11.9% during the forecast period for 2024-2031. Lipid-based drug delivery systems (LBDDS) are intended to increase the delivery and efficacy of drugs that are poorly soluble in water. These systems employ lipids as carriers to promote drug bioavailability, resulting in greater absorption in the body. LBDDS are employed in a variety of pharmaceutical applic...

ID: 2764 180 Pages September 2024

Bioactive Formulation for Functional F&B Market, Share & Trends Analysis Report, By Ingredient Type (Prebiotics, Probiotics, Adaptogens, Polyphenols, Omega-3 Fatty Acids, Antioxidants), By Formulation Technology (Encapsulation, Microemulsions, Liposomal Delivery), By Application, By Region, and Segment Forecasts, 2024-2031

The Bioactive Formulation for Functional F&B Market is predicted to grow at an 8.31% CAGR during the forecast period for 2024-2031. Bioactive formulations in functional food and beverages (F&B) utilize biologically active compounds that provide health benefits beyond basic nutrition. These formulations typically include ingredients such as polyphenols, prebiotics, probiotics, vitamins, peptides, and dietary fibers, which are targeted at...

ID: 2736 180 Pages September 2024

Non-Sterile Outsourcing Market, Share & Trends Analysis Report, By Dosage form (Oral, Ear & Eye, Nasal, Topical, Parenteral), By Application (Human Medication, Nutraceuticals, Cosmetics, Medical Devices, Veterinary Health), By Region, and Segment Forecasts, 2024-2031

The Non-Sterile Outsourcing Market Size is valued at USD 7.50 Bn in 2023 and is predicted to reach USD 10.81 Bn by the year 2031 at an 4.8% CAGR during the forecast period for 2024-2031. A compounded medication product can be either non-sterile or sterile and contains one or more active ingredients. While it is possible to manufacture compounded sterile products internally, an alternative is to contract with a 503B outsourcing facility outside...

ID: 2740 180 Pages September 2024

GMP Biologics Market, Share & Trends Analysis Report, By Type (Monoclonal Antibodies, Polyclonal Antibody), By Application (Hospitals, Clinics, Others), By Region, and Segment Forecasts, 2024-2031

The GMP Biologics Market Size is valued at USD 52.3 Bn in 2023 and is predicted to reach USD 153.9 Bn by the year 2031 at an 14.6% CAGR during the forecast period for 2024-2031. The term "Good Manufacturing Practice" (GMP) Biologics describes the manufacture of biologic pharmaceuticals by strict legal requirements intended to guarantee the effectiveness, safety, and quality of the final product. The World Health Organization (WHO) and other or...

ID: 2715 180 Pages August 2024

Medical Device Package Validation Market Size, Share & Trends Analysis Report, By Testing Type (Physical Testing, Microbial Testing, Chemical Testing, and Visual Testing), By Device Class (Class I Devices, Class II Devices, and Class III Devices)), By Nature, By Sales Channel, By Region, Forecasts, 2024-2031

The Medical Device Package Validation Market Size is predicted to grow at a 8.61% CAGR during the forecast period for 2024-2031. The whole process of packaging validation is the identification and management of materials and production factors influencing the capacity of a packaged product to satisfy acceptance criteria. Validation's outcomes provide various advantages. Process control and assurance are attained to fulfil the device package cr...

ID: 2701 180 Pages August 2024

Hematological Malignancies Drugs Market Size, Share & Trends Analysis Report By Drugs (Monoclonal Antibodies, CAR-T Cell Therapy), By Pipeline Products, By Indication (Leukemia, Lymphoma), By Region, And Segment Forecasts, 2024-2031

The Hematological Malignancies Drugs Market Size is estimated to grow at a CAGR of 14.2% during the forecast period for 2024-2031.  Hematologic malignancies are cancers that most often start in the bone marrow or the immune system cells. Lymphom, leukemia, and multiple myeloma are the three most common blood malignancies. The development of innovative agents has contributed to improved outcomes for cancer patients in recent years, re...

ID: 1211 180 Pages August 2024

Antibody Hit Generation and Screening Market Size, Share & Trends Analysis Distribution By Application (Cancer, Autoimmune Diseases, Infectious Diseases), Technologies (Hit Generation, Phage Display, Yeast Display, Ribosome Display, B-Cell Hybridoma Technology, Computational Tools, Screening), Antibody Type And Segment Forecasts, 2024-2031

The Antibody Hit Generation and Screening Market Size is predicted to grow at an 9.78% CAGR during the forecast period for 2024-2031. Antibody hit generation and screening is a vital step in developing therapeutic antibodies, focusing on identifying and selecting candidates that bind to a target antigen with high affinity and specificity. This process leverages various technologies like hybridoma technology, phage display, yeast display, ribos...

ID: 2667 180 Pages August 2024

Key Pharmaceutical Sub-Segments We Cover

CDMO & Contract Manufacturing

The pharmaceutical CDMO market is expanding rapidly as drug developers increasingly outsource manufacturing to reduce capital expenditure and accelerate time-to-market. Our CDMO reports cover small molecule contract manufacturing, biologics CDMO, fill-finish services, and continuous manufacturing outsourcing with competitive landscape analysis of leading CDMOs worldwide.

API & Drug Substance Manufacturing

Active pharmaceutical ingredient sourcing and manufacturing is a critical strategic decision for pharma companies. Our API reports analyze supply chain dynamics, pricing trends, geographic manufacturing shifts, and the growing demand for high-potency APIs, peptide APIs, and oligonucleotide synthesis.

Drug Delivery Systems

Innovation in drug delivery — from nasal and transdermal systems to lipid nanoparticle platforms and controlled-release formulations — is reshaping how therapeutics reach patients. We cover the full spectrum of delivery technologies including inhalation devices, implantable systems, and targeted nanoparticle carriers.

Oncology & Immuno-Oncology

Oncology remains the largest therapeutic area by R&D investment. Our reports cover bispecific antibodies, antibody-drug conjugates, checkpoint inhibitors, CAR-T therapies, radiopharmaceuticals, and companion diagnostics with pipeline analysis and competitive positioning.

Biosimilars & Biologics

The biosimilar market is driven by patent cliffs of blockbuster biologics and increasing regulatory clarity. We analyze biosimilar development pipelines, interchangeability trends, market penetration dynamics, and the competitive strategies of both originator and biosimilar manufacturers.

Why Choose InsightAce for Pharmaceutical Market Intelligence?

  • Original primary research — 15–25 KOL interviews per report with pharma executives, CDMO leaders, formulators, and regulatory experts
  • 10-year market forecasts — analyst-built models with top-down and bottom-up triangulation, covering 2026–2035
  • Competitive landscape — detailed profiling of 15–25 companies per report including revenue analysis, pipeline mapping, and strategic positioning
  • Segmentation depth — by type, application, technology, formulation, route of administration, end-user, and region
  • Post-purchase support — dedicated analyst hours for follow-up questions, custom data tables, and presentation-ready slides

Frequently Asked Questions

How many pharmaceutical market research reports does InsightAce publish?

InsightAce Analytic has published 340+ pharmaceutical market research reports covering drug development, CDMO outsourcing, API manufacturing, biosimilars, clinical trials, and specialty pharma with 10-year forecasts.

What pharmaceutical sub-segments does InsightAce cover?

We cover CDMO & contract manufacturing, API & drug substance, drug delivery systems, oncology & immuno-oncology, biosimilars & biologics, cell & gene therapy, rare diseases & orphan drugs, CNS & neurology, and clinical trials & CRO markets.

What is included in InsightAce pharmaceutical reports?

Each report includes 10-year market size forecasts, competitive landscape with 15-25 company profiles, segmentation by type, application, and region, 15-25 KOL interviews, and post-purchase analyst support.

Can I customize a pharmaceutical report?

Yes. Every report purchase includes free 10% customization. You can add countries, extend the forecast period, add company profiles, or request specific segmentation cuts.

How do I request a sample pharmaceutical report?

Click "Request Sample" on any report card to receive an executive summary, table of contents, and sample data tables delivered to your email.